Date: 2012-06-18
Type of information: Licensing agreement
Compound: ASP-08126 (Debio 1144)
Company: Debiopharm (Switzerland) Ascepion Pharmaceuticals (China)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
development
commercialisation
Action mechanism: ASP-08126 is a potent orally available small molecule that binds and inhibits several tyrosine kinase oncogenes implicated in many aspects of cancer development including tumour growth, metastasis, and tumour angiogenesis. ASP-08126 is expected to be effective in the treatment of various solid tumours as a mono-therapeutic agent or in combination with other anti-cancer therapies.
Disease: cancer
Details: * On June 18, 2012, Debiopharm and Ascepion Pharmaceuticals, a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have concluded an exclusive license agreement for the development and commercialisation of the dual-targeting kinase Inhibitor, ASP-08126 (Debio 1144), for the treatment of oncology diseases. This multikinase inhibitor is currently in pre-clinical development. and is expected to be effective in the treatment of various solid tumours as a mono-therapeutic agent or in combination with other anti-cancer therapies.
Financial terms:
Latest news: * On April 18, 2013, Suzhou Ascepion Pharmaceuticals, and Debiopharm have announced that Debiopharm will support further development in China of Debio 1144, currently in preclinical development for the treatment of a large spectrum of solid tumors. Debiopharm and Ascepion had previously signed a license agreement for the development and commercialization of this orally available multikinase inhibitor. After having generated positive preclinical results with the product, Debiopharm has decided to support Ascepion for further development of Debio 1144 in China as it is well designed for the treatment of certain types of cancers that are highly represented in China.
